A team led by Dr. Yeh Chia-Tsui, Associate Researcher at the National Defense Medical Center, has successfully developed chicken egg yolk-derived immunoglobulin Y (IgY) antibodies targeting a range of pathogens, including the novel coronavirus and anthrax bacteria. These antibodies have been shown to neutralize viruses and inhibit toxins, providing a new alternative for the prevention and treatment of infectious diseases.

Addressing the Threat of Pathogen Infections with IgY Antibodies

Pathogen infections continue to pose significant challenges to global public health. Traditionally, vaccines and antibody therapies have been the primary means of prevention and treatment. However, the development of vaccines is time-consuming and costly. In recent years, IgY antibodies have attracted considerable attention due to their unique characteristics, such as rapid production, low cost, and high safety. Despite these advantages, current IgY applications still face some limitations, such as unstable production yields and complex purification processes.

IgY Antibodies: A Highly Effective, Cost-Effective, and Broad-Spectrum Solution Against Infections

The research team utilized genetic engineering techniques to successfully induce chickens to produce high-specificity IgY antibodies targeting pathogens like the novel coronavirus, anthrax, and plague bacteria. These antibodies not only accurately identify pathogens but also effectively neutralize viruses, preventing them from infecting host cells. Additionally, these antibodies have the following advantages:

Broad-Spectrum Antiviral Activity: The antibodies exhibit high neutralizing activity against multiple virus strains, showing potential for broad-spectrum antiviral use.

High Safety: Due to their structural differences from mammalian immunoglobulins, IgY antibodies have a lower immunogenicity and are less likely to trigger allergic reactions.

High Yield, Low Cost: By utilizing chicken eggs for IgY antibody production, the process reduces production costs, shortens development time, and makes large-scale applications more feasible.

The Promising Future of IgY Antibodies in Disease Prevention and Treatment

Dr. Yeh Chia-Tsui states that these IgY antibodies hold significant potential for the future, with the possibility of developing them into novel antiviral drugs, vaccine adjuvants, and diagnostic reagents. Additionally, they could be applied in fields like food safety and environmental monitoring. The research team is committed to optimizing the antibody production process and collaborating with industry partners to accelerate the development and market introduction of these antibodies.

Resource (mandarin): 新型IgY抗體準確識別病原體 中和病毒對抗感染